<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sarcoma</journal-id><journal-id journal-id-type="publisher-id">SRCM</journal-id><journal-title>Sarcoma</journal-title><issn pub-type="ppub">1357-714X</issn><issn pub-type="epub">1369-1643</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19197386</article-id><article-id pub-id-type="pmc">2634844</article-id><article-id pub-id-type="doi">10.1155/2008/431019</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Genetic Profiling Differentiates Second Primary Tumors from Metastases in Adult Metachronous Soft Tissue Sarcoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fernebro</surname><given-names>Josefin</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Carneiro</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rydholm</surname><given-names>Anders</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Domanski</surname><given-names>Henryk A.</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Karlsson</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Borg</surname><given-names>&#x000c5;ke</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nilbert</surname><given-names>Mef</given-names></name><xref ref-type="aff" rid="I1"><sup>1, 4</sup></xref><xref ref-type="aff" rid="I4"/></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Oncology, Institute of Clinical Sciences, Lund University Hospital, 221 85 Lund, Sweden</aff><aff id="I2"><sup>2</sup>Department of Orthopedics, Institute of Clinical Sciences, Lund University Hospital, 221 85 Lund, Sweden</aff><aff id="I3"><sup>3</sup>Department of Pathology, Institute of Clinical Sciences, Lund University Hospital, 221 85 Lund, Sweden</aff><aff id="I4"><sup>4</sup>Clinical Research Centre, Hvidovre Hospital, Copenhagen University, 2650 Hvidovre, Denmark</aff><author-notes><corresp id="cor1">*Josefin Fernebro: <email>josefin.fernebro@med.lu.se</email></corresp><fn fn-type="other"><p>Recommended by Cyril Fisher</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>2</day><month>2</month><year>2009</year></pub-date><volume>2008</volume><elocation-id>431019</elocation-id><history><date date-type="received"><day>23</day><month>7</month><year>2008</year></date><date date-type="rev-recd"><day>7</day><month>10</month><year>2008</year></date><date date-type="accepted"><day>1</day><month>12</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Josefin Fernebro et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>					<italic>Purpose</italic>. Patients with soft tissue sarcomas (STS) are at increased risk of second primary malignancies, including a second STS, but distinction between metastases and a second primary STS is difficult. <italic>Patients and Methods</italic>. Array-based comparative genomic hybridization (aCGH) was applied to 30 multiple STS of the extremities and the trunk wall from 13 patients. Different histotypes were present with malignant fibrous histiocytomas/undifferentiated pleomorphic sarcomas being the predominant subtype. <italic>Results</italic>. aCGH profiling revealed genetic complexity with multiple gains and losses in all tumors. In an unsupervised hierarchical cluster analysis, similar genomic profiles and close clustering between the first and subsequent STS were identified in 5 cases, suggesting metastatic disease, whereas the tumors from the remaining 8 patients did not cluster and showed only weak pairwise correlation, suggesting development of second primary STS. <italic>Discussion</italic>. The similarities and dissimilarities identified in the first and second STS suggest that genetic profiles can be used to distinguish soft tissue metastases from second primary STS. The demonstration of genetically different soft tissue sarcomas in the same patient  suggests independent tumor origin and serves as a reminder to consider development of second primary STS, which has prognostic and therapeutic implications.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>The first observations of anincreased risk of secondary sarcoma development came from individuals treatedfor childhood cancers such as retinoblastoma, leukemia, Wilms' tumor, Hodgkin'slymphoma, and sarcoma [<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B13">13</xref>]. However,also adult soft tissue sarcoma (STS) patients have been shown to be at higherrisk of a second primary malignancy, with a particularly increased risk of asecond primary STS [<xref ref-type="bibr" rid="B14">14</xref>&#x02013;<xref ref-type="bibr" rid="B17">17</xref>]. STS havebeen associated with several hereditary syndromes, the most common being neurofibromatosisand the Li-Fraumeni syndrome [<xref ref-type="bibr" rid="B18">18</xref>]. Treatment-induced sarcomas include sarcomasassociated with Stewart-Treeves syndrome and radiation-induced angiosarcomas,which develop median 10 years after radiotherapy [<xref ref-type="bibr" rid="B19">19</xref>]. However, after exclusionof STS in neurofibromatosis patients and STS that developed in irradiatedfields, an increased risk of a second primary STS remains [<xref ref-type="bibr" rid="B17">17</xref>].  Metachronous STS has been described in 1% ofsarcoma patients [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B20">20</xref>] and this observation constitutes the basis forour study on similarities/differences in the genetic profiles of tumors frompatients with multiple STS. We applied array-based comparative genomichybridization (aCGH) that utilizes BAC clones with tiling coverage of the wholegenome and allows detailed copy-number analysis, to a series of 30 metachronous STS of different histopathologicalsubtypes from 13 patients.</p></sec><sec sec-type="section" id="sec2"><title>2. PATIENTS AND METHODS</title><sec id="sec2.1"><title>2.1. Patients</title><p>Adult patients (&#x02265;16 years of age)who developed two or more STS at different anatomical sites before developmentof any detectable pulmonary metastases were eligible for the study. Patients withneurofibromatosis type I and the Li-Fraumeni syndrome were excluded. In thesouthern Swedish cancer registry, 20 patients who fulfilled these criteria wereidentified. The tumors had been operated either at the musculoskeletal tumorcenter in Lund  (<italic>n</italic> = 24) or at local hospitals in the southern Swedish health care region (<italic>n</italic> = 6). The clinicopathological reports were reviewed to confirm tumor location and torule out that the second primary STS represented a local recurrence and the histopathologicalslides were reviewed by a sarcoma pathologist (H.D.) to confirm the diagnoses.</p><p>Frozen tumor tissue was availablefrom 16 tumors and paraffin-embedded tissue was used from 28 tumors without systematicdifferences related to tumor source. After DNA extraction, 7 individuals (14tumors) were excluded because of poor DNA quality in at least one of the tumorsfrom the same patient. High-quality aCGH data were obtained from 30 tumors (in15 of which DNA was extracted from frozen tissue) from 13 patients (<xref ref-type="table" rid="tab1">Table 1</xref>). These patients contributed with two to four STS and were mean 73 (28&#x02013;83) years at diagnosisof the first STS. The second STS developed median 3 (1&#x02013;7) years afterthe first STS. No neoadjuvant chemotherapy was given, and only one patient(case 5) had recieved postoperative chemotherapy after the first STS. Radiotherapy had been administered to four patients (postoperatively in case 5,6, and 8, and preoperatively in case 1), but none of the second STS developedwithin the irradiated field.</p><p>Clinical data for the 13 cases arepresented in <xref ref-type="table" rid="tab1">Table 1</xref>. The lower extremity was the most common tumor site (16tumors) and 28 tumors were high-grade (grades 3 and 4 on a 4-tiered scale). Thefirst STS included eight malignant fibrous histiocytomas/undifferentiatedpleomorphic sarcomas (MFH/UPS), two leiomyosarcomas, two malignant peripheralnerve sheath tumors (MPNST), and one pleomorphic liposarcoma. Thehistopathological diagnosis of the second STS differed from the first in twopatients; a leiomyosarcoma was diagnosed in a patient with two prior MFH/UPSand a leiomyosarcoma was diagnosed in a patient previously operated on for anMPNST. In the remaining patients, including the three cases from which three or four distinct tumors were analyzed, multiple STS of the samehistopathological type were diagnosed.</p><p>In 9/13 patients the STS developedat different anatomical locations, for example, different extremities orextremity and trunk wall. Three patients developed metachronous STS in the sameextremity but at different locations, for example, lower leg and thigh (cases8, 12, and 13) and one patient (no. 7) developed two STS in the same extremity;a deep-seated leiomyosarcoma in the medial thigh and five years later a subcutaneousleiomyosarcoma in the lateral part of the thigh (<xref ref-type="table" rid="tab1">Table 1</xref>). Clinical follow-upwas complete for a minimum of 8 years for the survivors. During follow-up, twopatients (cases 12 and 13) developed local recurrences, 1 and 10 years afterprimary surgery. Lung metastases developed in 5/13 patients, median 50 (range15&#x02013;51) months afterdiagnosis of the primary tumor. Apart from the metachronous STS, two patients(cases 4 and 7) developed adenocarcinomas of the breast and the colon,respectively. Ethical permission for the study was granted from the Lund University ethics committee.</p></sec><sec id="sec2.2"><title>2.2. DNA extraction and array-based comparativegenomic hybridization</title><p>Genomic DNA from frozen (<italic>n</italic> = 15) andparaffin-embedded (<italic>n</italic> = 15) tumors was extracted using the Wizard Genomic DNAPurification kit (Promega, Madison, WI) and overnight proteinase-K digestiontreatment followed by phenol-chloroform purification. When paraffin-embeddedtissue was used, a fresh 4-<italic>&#x003bc;</italic>m section was obtained, stained with hematoxylin&#x00026; eosin and a representative tumor area was chosen. Thereafter, 1-mm tissuecores were obtained and used for DNA extraction. The tissue cores werepretreated in xylene before proteinase-K treatment and phenol-chloroformpurification. DNA quality was checked using a Ready-To-Go RAPD analysis kit(Amersham Biosciences, Buckinghamshire, UK), and the concentration was measuredusing a Nano drop (NanoDrop Technologies, Wilmington, Del, USA). Commercial genomicmale DNA, derived from a pool of healthy individuals, was used as a reference(Promega, Madison, Wiss, USA). CyDye coupling/labeling was carried outusing a random labeling kit (Invitrogen Life Technologies, Carlsbad, Calif, USA)according to the manufacturer's recommendations. In short, 2-<italic>&#x003bc;</italic>g genomic tumorDNA and reference DNA were differentially labeled with fluorescent dyes, Cy3for tumor tissue, and Cy5 for reference DNA. After a purification step, thesewere pooled, mixed with COT-1 DNA to block repetitive DNA sequences, dehydratedand resuspended in a formamide-based buffer (Invitrogen). The labeled DNA wasthen applied to arrays pretreated in washing solutions (Pronto! MicroarrayReagent System, Corning Labsystems, Corning, NY, USA) and hybridization wasperformed for 48&#x02013;72 hours at 37&#x000b0;C. The incubation was performed under cover slips forthe DNA isolated from the frozen tumor material whereas the MAUI hybridizationSystem (BioMicro systems Inc., Salt Lake City, Utah, USA) wasused for the DNA derived from paraffin-embedded tumors. Dye-swaps (i.e.,complementary hybridization in which Cy5 was used for tumor tissue and Cy3 for reference DNA) were used in three cases and allowed subtraction of dye-related noise. The slides were treated in post-hybridizationwashing solutions and finally scanned using an Agilent Microarray scanner(Agilent Technologies, Palo Alto, Calif, USA).</p></sec><sec id="sec2.3"><title>2.3. BAC array platform</title><p>The BAC array slides used wereproduced at the Swegene DNA Microarray Resource Center,Department of Oncology, Lund University. These have anaverage resolution of 80 kb and contain a total of 32 433 BAC clones fromthe 32 k human genome high-resolution BAC rearrayed clone set, version 1.0 fromthe BACPAC Resource Center at Children's Hospital Oakland Research Institute(Oakland, Calif, USA) (<ext-link ext-link-type="uri" xlink:href="http://bacpac.chori.org/">http://bacpac.chori.org/</ext-link>). The clones provide &#x0003e;99% coverage of the fingerprint map and current sequenceassembly with a resolution of 100 kb.</p></sec><sec id="sec2.4"><title>2.4. Data analysis</title><p>Image analysis and data extractionwere carried out using GenePix Pro 4.1.1.4 version (Axon Instruments Inc.,Foster City, CA, USA) and the quantified data matrix was then uploaded into theweb-based BioArray Software Environment (BASE; <ext-link ext-link-type="uri" xlink:href="http://gothmog.thep.lu.se/int/index">http://gothmog.thep.lu.se/int/index</ext-link>) [<xref ref-type="bibr" rid="B21">21</xref>], where all data management and analysis were carried out. Thebackground correction and intensities of Cy3 and Cy5 were calculated using themedian feature and median-local background intensities of the uploaded files,and the intensity ratios were calculated using the background corrected spotintensities by calculating the log<sub>2</sub> ratios of tumor to referenceintensity. In BASE a preliminary filter, based on the flagging in the imageanalysis, was applied, and spots with a diameter &#x0003c;55 <italic>&#x003bc;</italic>m and a signal tonoise (SNR) ratio &#x02264;3 in the tumor or reference channel were flagged as &#x0201c;bad&#x0201d;and filtered away from further analysis. The intensity-dependent LOWESSalgorithm [<xref ref-type="bibr" rid="B22">22</xref>] was used to normalize the data within individual arrays. Tocorrect for spatial bias, the data were normalized within groups of 8 print-tipblocks. A moving average smoothing algorithm with a 250 kbp sliding window wasthen applied, and a BASE-adapted CGH-plotter software was used to identifyregions of gains and losses [<xref ref-type="bibr" rid="B23">23</xref>]. In the CGH-plotter, each clone was assigned acalculated level log<sub>2</sub> ratio value, corresponding to the level thatthe clone belongs to, in order to reduce the noise. Hereafter an unsupervisedhierarchical cluster analysis, using the Pearson correlation distance metricand the average linkage method, was applied to the data derived from theCGH-plotter (the TMeV application from the TM<sub>4</sub> microarray software suite was used; <ext-link ext-link-type="uri" xlink:href="http://www.tm4.org/mev.html">http://www.tm4.org/mev.html</ext-link>). The CGH-plotter was also used to generate a ternary scale, where all clones were designated gained, lost or unchanged. These values were used to calculate the percentageof altered clones in each assay and the mean number of altered clones in tumorsubgroups. Pearson correlation was used to determine the correlation betweentumors within the same individual, based on the number of altered clones. Gainsand losses were defined as a log<sub>2</sub> ratio &#x000b1;0.2. Amplifications weredefined as clones with a log<sub>2</sub> ratio &#x02265;0.5, whereas high-levelamplifications were defined as a log<sub>2</sub> ratio &#x02265;1.5. Homozygousdeletions were suspected when the log<sub>2</sub> ratio was &#x02264;1.5.</p></sec></sec><sec sec-type="section" id="sec3"><title>3. RESULTS</title><p>Genomic profiles from the 30metachronous STS of five different histopathological subtypes revealed multiplegains and losses and identified several high-level amplifications (HLA) and homozygousdeletions (<xref ref-type="table" rid="tab2">Table 2</xref>). The alterations affected mean 39 (9&#x02013;70)% of the wholegenome with 19% amplifications and 20% deletions. When the first STS (<italic>n</italic> = 13)were compared to the subsequent STS (<italic>n</italic> = 17) a small difference in the totalnumber of alterations was found with 35 (16&#x02013;54)% and, 42 (9&#x02013;70)% of thegenome altered, respectively. Several recurrent aberrations were identifiedwith the most frequent changes (present in &#x0003e;60% of the tumors) beingdeletions of 10q24.3&#x02013;25.2, 13q12.1&#x02013;12.2, 13q21.1&#x02013;21.2, 16q13&#x02013;23.2, 18q12.2&#x02013;12.3, andamplifications of 1q21.3&#x02013;23.1 and 19p13.3.</p><p>Unsupervised hierarchical clusteranalysis, based on the ~27 000 clones that survived the filters in BASE,revealed close clustering of the tumors from five individuals withoutsignificant differences between the first and subsequent STS (43% and 41% ofthe genome altered) (<xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="table" rid="tab1">Table 1</xref>, cases 1, 2, 6, 9, and 12). Thesetumor pairs showed strong similarities between the genomic plots (<xref ref-type="fig" rid="fig2">Figure 2(a)</xref>) witha mean correlation of 0.7 (0.5&#x02013;0.9).  The many shared alterations outnumbered thefew differences in all five cases and deletions identified in the first tumorwere always present in the second STS. The median time interval between thefirst and second STS in these five patients was 1 (1&#x02013;7) year, and twoof these patients subsequently developed lung metastases. In the remaining eightcases STS from the same individual did not cluster together and showed asignificantly weaker correlation, mean 0.1 (0&#x02013;0.4). Thesetumors had pronounced intertumor variability (30% of the genome being alteredin the first tumor compared to 42% in the subsequent tumors), which wascomparable to the interpatient variability, which had a mean correlation of 0.1(0.04&#x02013;0.2). In four ofthese cases, deletions present in the first tumor were not present in thesubsequent tumor, which supports independent tumor origin. The second STS inthese eight cases developed median 4 (1&#x02013;5) years afterthe first STS and three of the patients later developed pulmonary metastases.</p></sec><sec sec-type="section" id="sec4"><title>4. DISCUSSION</title><p>Despite multidisciplinary andmultimodality treatment, distant metastases develop in about 30% of STSpatients. Hematogenous, pulmonary metastases predominate, whereas lymphaticspread occurs in &#x0003c;5% of the patients [<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B24">24</xref>]. Soft tissue metastases arerare and have mainly been reported in liposarcomas [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B25">25</xref>]. Development of synchronousor metachronous STS has been described in several case studies, but it remainsa rare clinical presentation and the interpretations hereof have varied [<xref ref-type="bibr" rid="B25">25</xref>&#x02013;<xref ref-type="bibr" rid="B29">29</xref>]. Epidemiological data support an increased risk of a secondary primary sarcomaamong adult STS patients [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B17">17</xref>]. In order to reduce bias from inclusion offamilial sarcoma syndromes, we excluded multiple sarcoma patients diagnosed withneurofibromatosis or the Li-Fraumeni syndrome. The only patient who developedmore than one MPNST was carefully examined without any sign of neurofibromatosis(until death 3 years later). Sinceonly one patient had received adjuvant chemotherapy after the first STS andnone of the second STS developed in irradiated fields, the second STS studiedare unlikely to represent treatment-induced secondary tumors.</p><p>Application of CGH in STS has mainlyinvolved leiomyosarcoma and MFH/UPS and has in these highly malignant andpleomorphic STS subtypes demonstrated extensive genomic complexity withrecurrent copy number changes, including losses of 2p, 2q, 10q, 11q, and 13q andgains of 1q, 5p, 8q, and 17p [<xref ref-type="bibr" rid="B30">30</xref>&#x02013;<xref ref-type="bibr" rid="B36">36</xref>]. Several ofthese recurrent changes were also identified among the 30 STS in this studywith the most frequent being deletions of 10q24.3&#x02013;25.2, 13q12.1&#x02013;12.2, 13q21.1&#x02013;21.2, 16q13&#x02013;23.2, 18q12.2&#x02013;12.3, andamplifications of 1q21.3&#x02013;23.1 and 19p13.3. In order to obtain as many tumor pairs as possible, frozen as well asparaffin-embedded tumor tissue was used. Among the tumors from whichhigh-quality DNA was obtained, no differences were identified related to tumorsource (<xref ref-type="table" rid="tab1">Table 1</xref>). When the genomic profiles from the different tumor pairs werecompared, five pairs showed highly correlated genomic profiles suggestive ofmetastatic disease, whereas eight cases showed different profiles suggestive ofdistinct primary STS. In the latter STS, the differences by far outnumbered thesimilarities, which resulted in a weak correlation, which was comparable to theinterpatient variability. Importantly, there was no systematic difference insample preparation methodology between the two groups suggestive of metastaticdisease and distinct primary STS, respectively. The similarities anddifferences were evident in an unsupervised hierarchical cluster analysis (<xref ref-type="fig" rid="fig1">Figure 1</xref>) in which the five former tumor pairs clustered closely, whereas the latter eightdid not.</p><p>Previous reports of multiple STShave predominantly involved liposarcomas. In a mixed series of nine STSpatients who developed synchronous and metachronous STS, Grobemyer et al. identified liposarcomas (<italic>n</italic> = 5)and gastrointestinal stromal tumors (<italic>n</italic> = 5) as the most frequent subtypes whereasBlair et al. reported 16patients with multiple STS of whom nine had liposarcomas [<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B37">37</xref>]. Our study onlyincluded successfully analyzed liposarcomas from one patient (case no. 6) whodeveloped four liposarcomas in four years without signs of lung metastases and diedfrom locally advanced tumor masses 22 months later. Antonescu et al. applied Southern blot analysisto tumors from six patients with multifocal myxoid liposarcomas and herebyverified monoclonality, thus demonstrating that multiple myxoid liposarcomas inthe same individual most likely represent recurrent disease [<xref ref-type="bibr" rid="B16">16</xref>]. Similargenetic profiles were in our series present in metachronous STS of the samehistopathological types; three MFH/UPS, one liposarcoma, and one leiomyosarcoma,which developed with median 1 year interval. Subsequent development of lungmetastases occurred in two of these five patients (<xref ref-type="table" rid="tab1">Table 1</xref>). Previous studiesthat have examined genetic differences between primary and recurrent STS havebeen carried out using conventional CGH and have demonstrated increasing geneticcomplexity from primary STS to a localrecurrence [<xref ref-type="bibr" rid="B38">38</xref>&#x02013;<xref ref-type="bibr" rid="B40">40</xref>]. However, the issue of development of second primary STS has to ourknowledge not been addressed using genetic profiling. We demonstrate strikinglysimilar genetic profiles in the five STS likely representing soft tissuemetastases with mean 43% and 41% of the genome altered and several shareddeletions identified. This stands in contrast to the eight STS patients fromwhich the metachronous STS showed different genetic profiles. Among these,multiple histologic subtypes (i.e., MFH/UPS, MPNST, and leiomyosarcomas) werepresent and four of the deletions identified in the primary tumors were notfound in the second STS. In summary, the clinical presentation, histopathology,and the genetic profile support independent sarcoma origin in 8 of the 13patients (<xref ref-type="table" rid="tab1">Table 1</xref>). Although development of metachronous STS is rare, ourdemonstration of different genetic profiles in the majority of these casesserves as a reminder to consider independent tumor origin, which has implicationsfor the choice of therapy, for example, use of adjuvant chemo- and/orradiotherapy after surgery for a second STS that should not per se be perceived to represent metastaticdisease.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>Financial support was granted fromthe Swedish Cancer Fund, the Swedish Research Council, the Swedish Children'sCancer Fund, and the Nilsson Cancer Fund.</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Breslow</surname><given-names>NE</given-names></name><name><surname>Takashima</surname><given-names>JR</given-names></name><name><surname>Whitton</surname><given-names>JA</given-names></name><name><surname>Moksness</surname><given-names>J</given-names></name><name><surname>D'Angio</surname><given-names>GJ</given-names></name><name><surname>Green</surname><given-names>DM</given-names></name></person-group><article-title>Second malignant neoplasms following treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>1995</year><volume>13</volume><issue>8</issue><fpage>1851</fpage><lpage>1859</lpage><pub-id pub-id-type="pmid">7636528</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moll</surname><given-names>AC</given-names></name><name><surname>Imhof</surname><given-names>SM</given-names></name><name><surname>Bouter</surname><given-names>LM</given-names></name><name><surname>Tan</surname><given-names>KEW</given-names></name></person-group><article-title>Second primary tumors in patients with retinoblastoma. A review of the literature</article-title><source><italic>Ophthalmic Genetics</italic></source><year>1997</year><volume>18</volume><issue>1</issue><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">9134547</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beaty</surname><given-names>O</given-names><suffix>III</suffix></name><name><surname>Hudson</surname><given-names>MM</given-names></name><name><surname>Greenwald</surname><given-names>C</given-names></name><etal/></person-group><article-title>Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>1995</year><volume>13</volume><issue>3</issue><fpage>603</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">7884422</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neglia</surname><given-names>JP</given-names></name><name><surname>Friedman</surname><given-names>DL</given-names></name><name><surname>Yasui</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>2001</year><volume>93</volume><issue>8</issue><fpage>618</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">11309438</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bisogno</surname><given-names>G</given-names></name><name><surname>Sotti</surname><given-names>G</given-names></name><name><surname>Nowicki</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Soft tissue sarcoma as a second malignant neoplasm in thepediatric age group</article-title><source><italic>Cancer</italic></source><year>2004</year><volume>100</volume><issue>8</issue><fpage>1758</fpage><lpage>1765</lpage><pub-id pub-id-type="pmid">15073867</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>O</given-names></name><name><surname>Easton</surname><given-names>D</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Gilham</surname><given-names>C</given-names></name><name><surname>Jay</surname><given-names>M</given-names></name><name><surname>Peto</surname><given-names>J</given-names></name></person-group><article-title>Lifetime risks of common cancers among retinoblastoma survivors</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>2004</year><volume>96</volume><issue>5</issue><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">14996857</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kleinerman</surname><given-names>RA</given-names></name><name><surname>Tucker</surname><given-names>MA</given-names></name><name><surname>Tarone</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2005</year><volume>23</volume><issue>10</issue><fpage>2272</fpage><lpage>2279</lpage><pub-id pub-id-type="pmid">15800318</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heyn</surname><given-names>R</given-names></name><name><surname>Haeberlen</surname><given-names>V</given-names></name><name><surname>Newton</surname><given-names>WA</given-names></name><etal/></person-group><article-title>Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>1993</year><volume>11</volume><issue>2</issue><fpage>262</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">8426203</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pratt</surname><given-names>CB</given-names></name><name><surname>Meyer</surname><given-names>WH</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><etal/></person-group><article-title>Second malignant neoplasms occuring in survivors of osteosarcoma</article-title><source><italic>Cancer</italic></source><year>1997</year><volume>80</volume><issue>5</issue><fpage>960</fpage><lpage>965</lpage><pub-id pub-id-type="pmid">9307198</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paulussen</surname><given-names>M</given-names></name><name><surname>Ahrens</surname><given-names>S</given-names></name><name><surname>Lehnert</surname><given-names>M</given-names></name><etal/></person-group><article-title>Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study</article-title><source><italic>Annals of Oncology</italic></source><year>2001</year><volume>12</volume><issue>11</issue><fpage>1619</fpage><lpage>1630</lpage><pub-id pub-id-type="pmid">11822764</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bacci</surname><given-names>G</given-names></name><name><surname>Longhi</surname><given-names>A</given-names></name><name><surname>Barbieri</surname><given-names>E</given-names></name><etal/></person-group><article-title>Second malignancy in 597 patients with Ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999</article-title><source><italic>Journal of Pediatric Hematology/Oncology</italic></source><year>2005</year><volume>27</volume><issue>10</issue><fpage>517</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">16217253</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bassal</surname><given-names>M</given-names></name><name><surname>Mertens</surname><given-names>AC</given-names></name><name><surname>Taylor</surname><given-names>L</given-names></name><etal/></person-group><article-title>Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2006</year><volume>24</volume><issue>3</issue><fpage>476</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">16421424</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>RJ</given-names></name><name><surname>Curtis</surname><given-names>RE</given-names></name><name><surname>Inskip</surname><given-names>PD</given-names></name><name><surname>Fraumeni</surname><given-names>JF</given-names><suffix>Jr.</suffix></name></person-group><article-title>The risk of developing second cancers among survivors of childhood soft tissue sarcoma</article-title><source><italic>Cancer</italic></source><year>2005</year><volume>103</volume><issue>11</issue><fpage>2391</fpage><lpage>2396</lpage><pub-id pub-id-type="pmid">15852362</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merimsky</surname><given-names>O</given-names></name><name><surname>Kollender</surname><given-names>Y</given-names></name><name><surname>Issakov</surname><given-names>J</given-names></name><etal/></person-group><article-title>Multiple primary malignancies in association with soft tissue sarcomas</article-title><source><italic>Cancer</italic></source><year>2001</year><volume>91</volume><issue>7</issue><fpage>1363</fpage><lpage>1371</lpage><pub-id pub-id-type="pmid">11283938</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tateishi</surname><given-names>U</given-names></name><name><surname>Hasegawa</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><etal/></person-group><article-title>Incidence of multiple primary malignancies in a cohort of adult patients with soft tissue sarcoma</article-title><source><italic>Japanese Journal of Clinical Oncology</italic></source><year>2005</year><volume>35</volume><issue>8</issue><fpage>444</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">16024533</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antonescu</surname><given-names>CR</given-names></name><name><surname>Elahi</surname><given-names>A</given-names></name><name><surname>Healey</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements</article-title><source><italic>Clinical Cancer Research</italic></source><year>2000</year><volume>6</volume><issue>7</issue><fpage>2788</fpage><lpage>2793</lpage><pub-id pub-id-type="pmid">10914725</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernebro</surname><given-names>J</given-names></name><name><surname>Bladstr&#x000f6;m</surname><given-names>A</given-names></name><name><surname>Rydholm</surname><given-names>A</given-names></name><etal/></person-group><article-title>Increased risk of malignancies in a population-based study of 818 soft-tissue sarcoma patients</article-title><source><italic>British Journal of Cancer</italic></source><year>2006</year><volume>95</volume><issue>8</issue><fpage>986</fpage><lpage>990</lpage><pub-id pub-id-type="pmid">17008869</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>HT</given-names></name><name><surname>Deters</surname><given-names>CA</given-names></name><name><surname>Hogg</surname><given-names>D</given-names></name><name><surname>Lynch</surname><given-names>JF</given-names></name><name><surname>Kinarsky</surname><given-names>Y</given-names></name><name><surname>Gatalica</surname><given-names>Z</given-names></name></person-group><article-title>Familial sarcoma: challenging pedigrees</article-title><source><italic>Cancer</italic></source><year>2003</year><volume>98</volume><issue>9</issue><fpage>1947</fpage><lpage>1957</lpage><pub-id pub-id-type="pmid">14584079</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cormier</surname><given-names>JN</given-names></name><name><surname>Pollock</surname><given-names>RE</given-names></name></person-group><article-title>Soft tissue sarcomas</article-title><source><italic>CA: A Cancer Journal for Clinicians</italic></source><year>2004</year><volume>54</volume><issue>2</issue><fpage>94</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">15061599</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>SL</given-names></name><name><surname>Lewis</surname><given-names>JJ</given-names></name><name><surname>Leung</surname><given-names>D</given-names></name><name><surname>Woodruff</surname><given-names>J</given-names></name><name><surname>Brennan</surname><given-names>MF</given-names></name></person-group><article-title>Multifocal extremity sarcoma: an uncommon and controversial entity</article-title><source><italic>Annals of Surgical Oncology</italic></source><year>1998</year><volume>5</volume><issue>1</issue><fpage>37</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">9524706</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saal</surname><given-names>LH</given-names></name><name><surname>Troein</surname><given-names>C</given-names></name><name><surname>Vallon-Christersson</surname><given-names>J</given-names></name><name><surname>Gruvberger</surname><given-names>S</given-names></name><name><surname>Borg</surname><given-names>&#x000c5;</given-names></name><name><surname>Peterson</surname><given-names>C</given-names></name></person-group><article-title>BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data</article-title><source><italic>Genome Biology</italic></source><year>2002</year><volume>3</volume><issue>8</issue><fpage>1</fpage><lpage>6</lpage><comment>Article ID software0003.</comment></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>YH</given-names></name><name><surname>Dudoit</surname><given-names>S</given-names></name><name><surname>Luu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation</article-title><source><italic>Nucleic Acids Research</italic></source><year>2002</year><volume>30</volume><issue>4, article e15</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">11752241</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Autio</surname><given-names>R</given-names></name><name><surname>Hautaniemi</surname><given-names>S</given-names></name><name><surname>Kauraniemi</surname><given-names>P</given-names></name><etal/></person-group><article-title>CGH-Plotter: MATLAB toolbox for CGH-data analysis</article-title><source><italic>Bioinformatics</italic></source><year>2003</year><volume>19</volume><issue>13</issue><fpage>1714</fpage><lpage>17153</lpage><pub-id pub-id-type="pmid">15593402</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>Y</given-names></name><name><surname>Coit</surname><given-names>DG</given-names></name><name><surname>Woodruff</surname><given-names>JM</given-names></name><name><surname>Brennan</surname><given-names>MF</given-names></name></person-group><article-title>Lymph node metastasis from soft tissue sarcoma in adults: analysis of data from a prospective database of 1772 sarcoma patients</article-title><source><italic>Annals of Surgery</italic></source><year>1993</year><volume>217</volume><issue>1</issue><fpage>72</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">8424704</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riva</surname><given-names>P</given-names></name><name><surname>Dalpr&#x000e0;</surname><given-names>L</given-names></name><name><surname>Gualandri</surname><given-names>V</given-names></name><etal/></person-group><article-title>19p deletion in recurring leiomyosarcoma lesions from the same patient</article-title><source><italic>Cancer Genetics and Cytogenetics</italic></source><year>2000</year><volume>119</volume><issue>2</issue><fpage>102</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">10867143</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alho</surname><given-names>A</given-names></name><name><surname>Eeg Larsen</surname><given-names>T</given-names></name></person-group><article-title>A case of multifocal liposarcoma?</article-title><source><italic>Acta Orthopaedica Scandinavica</italic></source><year>1992</year><volume>63</volume><issue>1</issue><fpage>98</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">1738982</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Koga</surname><given-names>Y</given-names></name><name><surname>Onitsuka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Primary liposarcoma of the mediastinum&#x02014;a case report and review of the literature</article-title><source><italic>The Japanese Journal of Surgery</italic></source><year>1986</year><volume>16</volume><issue>4</issue><fpage>277</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">3773360</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>DC</given-names></name><name><surname>de Oliveira Filho</surname><given-names>RS</given-names></name><name><surname>Bevilacqua</surname><given-names>RG</given-names></name><name><surname>Falzoni</surname><given-names>R</given-names></name><name><surname>Birolini</surname><given-names>D</given-names></name></person-group><article-title xml:lang="PT">Multicentric myxoid, metachronous and synchronous and multifocal liposarcoma: report of a case</article-title><source><italic>Revista do Hospital das Clinicas de Faculdade de Medicina da Universidade de Sao Paulo</italic></source><year>1994</year><volume>49</volume><issue>5</issue><fpage>217</fpage><lpage>220</lpage><comment>(Portuguese).</comment></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wa</surname><given-names>CV</given-names></name><name><surname>DeVries</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>YY</given-names></name><name><surname>Waldman</surname><given-names>FM</given-names></name><name><surname>Hwang</surname><given-names>ES</given-names></name></person-group><article-title>Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors</article-title><source><italic>Modern Pathology</italic></source><year>2005</year><volume>18</volume><issue>4</issue><fpage>591</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">15696129</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meza-Zepeda</surname><given-names>LA</given-names></name><name><surname>Kresse</surname><given-names>SH</given-names></name><name><surname>Barragan-Polania</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas</article-title><source><italic>Cancer Research</italic></source><year>2006</year><volume>66</volume><issue>18</issue><fpage>8984</fpage><lpage>8993</lpage><pub-id pub-id-type="pmid">16982739</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Rifai</surname><given-names>W</given-names></name><name><surname>Sarlomo-Rikala</surname><given-names>M</given-names></name><name><surname>Knuutila</surname><given-names>S</given-names></name><name><surname>Miettinen</surname><given-names>M</given-names></name></person-group><article-title>DNA copy number changes in development and progression in leiomyosarcomas of soft tissues</article-title><source><italic>American Journal of Pathology</italic></source><year>1998</year><volume>153</volume><issue>3</issue><fpage>985</fpage><lpage>990</lpage><pub-id pub-id-type="pmid">9736047</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Larramendy</surname><given-names>ML</given-names></name><name><surname>Kaur</surname><given-names>S</given-names></name><name><surname>Svarvar</surname><given-names>C</given-names></name><name><surname>B&#x000f6;hling</surname><given-names>T</given-names></name><name><surname>Knuutila</surname><given-names>S</given-names></name></person-group><article-title>Gene copy number profiling of soft-tissue leiomyosarcomas by array-comparative genomic hybridization</article-title><source><italic>Cancer Genetics and Cytogenetics</italic></source><year>2006</year><volume>169</volume><issue>2</issue><fpage>94</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">16938566</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>W-H</given-names></name><name><surname>Wejde</surname><given-names>J</given-names></name><name><surname>&#x000c5;hl&#x000e9;n</surname><given-names>J</given-names></name><name><surname>Pang</surname><given-names>S-T</given-names></name><name><surname>Lui</surname><given-names>W-O</given-names></name><name><surname>Larsson</surname><given-names>C</given-names></name></person-group><article-title>Characterization of large chromosome markers in a malignant fibrous histiocytoma by spectral karyotyping, comparative genomic hybridization (CGH), and array CGH</article-title><source><italic>Cancer Genetics and Cytogenetics</italic></source><year>2004</year><volume>150</volume><issue>1</issue><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15041220</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Derr&#x000e9;</surname><given-names>J</given-names></name><name><surname>Lagac&#x000e9;</surname><given-names>R</given-names></name><name><surname>Nicolas</surname><given-names>A</given-names></name><etal/></person-group><article-title>Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas</article-title><source><italic>Laboratory Investigation</italic></source><year>2001</year><volume>81</volume><issue>2</issue><fpage>211</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">11232643</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabah</surname><given-names>M</given-names></name><name><surname>Cummins</surname><given-names>R</given-names></name><name><surname>Leader</surname><given-names>M</given-names></name><name><surname>Kay</surname><given-names>E</given-names></name></person-group><article-title>Leiomyosarcoma and malignant fibrous histiocytoma share similar allelic imbalance pattern at 9p</article-title><source><italic>Virchows Archiv</italic></source><year>2005</year><volume>446</volume><issue>3</issue><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">15731925</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>YL</given-names></name><name><surname>Bae</surname><given-names>S</given-names></name><name><surname>Koo</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Array comparative genomic hybridization analysis of uterine leiomyosarcoma</article-title><source><italic>Gynecologic Oncology</italic></source><year>2005</year><volume>99</volume><issue>3</issue><fpage>545</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">16125217</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grobmyer</surname><given-names>SR</given-names></name><name><surname>Luther</surname><given-names>N</given-names></name><name><surname>Antonescu</surname><given-names>CR</given-names></name><name><surname>Singer</surname><given-names>S</given-names></name><name><surname>Brennan</surname><given-names>MF</given-names></name></person-group><article-title>Multiple primary soft tissue sarcomas</article-title><source><italic>Cancer</italic></source><year>2004</year><volume>101</volume><issue>11</issue><fpage>2633</fpage><lpage>2635</lpage><pub-id pub-id-type="pmid">15494976</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orndal</surname><given-names>C</given-names></name><name><surname>Mandahl</surname><given-names>N</given-names></name><name><surname>Willen</surname><given-names>H</given-names></name><name><surname>Rydholm</surname><given-names>A</given-names></name><name><surname>Mitelman</surname><given-names>F</given-names></name></person-group><article-title>Cytogenetic evolution in primary tumors, local recurrences, and pulmonary metastases of two soft tissue sarcomas</article-title><source><italic>Clinical and Experimental Metastasis</italic></source><year>1993</year><volume>11</volume><issue>5</issue><fpage>401</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">8375115</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tarkkanen</surname><given-names>M</given-names></name><name><surname>Huuhtanen</surname><given-names>R</given-names></name><name><surname>Virolainen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparison of genetic changes in primary sarcomas and their pulmonary metastases</article-title><source><italic>Genes Chromosomes and Cancer</italic></source><year>1999</year><volume>25</volume><issue>4</issue><fpage>323</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">10398425</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Popov</surname><given-names>P</given-names></name><name><surname>Virolainen</surname><given-names>M</given-names></name><name><surname>Tukiainen</surname><given-names>E</given-names></name><etal/></person-group><article-title>Primary soft tissue sarcoma and its local recurrence: genetic changes studied by comparative genomic hybridization</article-title><source><italic>Modern Pathology</italic></source><year>2001</year><volume>14</volume><issue>10</issue><fpage>978</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">11598167</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Unsupervised hierarchical cluster analysis of all 30 soft tissue sarcomas from13 patients. The analysis was based on the ~17 000 clones that survivedthe preprocessing filters, and close clustering of the metachronous STS was demonstratedin 5 patients (case 1, 2, 6, 9, and 12 marked with different colours), whereasthe STS from the remaining 8 patients were scatter in the analysis. Clusteringwas done using the TMeV application from the TM<sub>4</sub> microarray software suit.</p></caption><graphic xlink:href="SRCM2008-431019.001"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Superpositionof whole genome plots from two different tumors from the same patient showing (a)similarities in gene copy number changes in two liposarcomas (case 6). (b) Differencesin gene copy number changes in two malignant fibrous histiocytomas (case 3).</p></caption><graphic xlink:href="SRCM2008-431019.002"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Summary of clinical data from the 30 STS analyzed from 13 patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Case no.</th><th align="center" rowspan="1" colspan="1">Sex</th><th align="center" rowspan="1" colspan="1">Age</th><th align="center" rowspan="1" colspan="1">Site</th><th align="center" rowspan="1" colspan="1">Type</th><th align="center" rowspan="1" colspan="1">Years after first tumor</th><th align="center" rowspan="1" colspan="1">Site</th><th align="center" rowspan="1" colspan="1">Type</th><th align="center" rowspan="1" colspan="1">Years after first tumor</th><th align="center" rowspan="1" colspan="1">Site</th><th align="center" rowspan="1" colspan="1">Type</th><th align="left" rowspan="1" colspan="1">Follow-up status/months</th><th align="center" rowspan="1" colspan="1">Tumor source frozen/paraffin</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" colspan="3" rowspan="1"><italic>First tumor</italic></td><td align="center" colspan="3" rowspan="1"><italic>Second tumor</italic></td><td align="center" colspan="3" rowspan="1"><italic>Third tumor</italic></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="13" rowspan="1"><hr/></td></tr><tr><td align="center" colspan="13" rowspan="1"><italic>Similar genomic profiles suggestive of metastatic disease</italic></td></tr><tr><td align="center" colspan="13" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">Trunk wall</td><td align="center" rowspan="1" colspan="1">LMS</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Left cheek</td><td align="center" rowspan="1" colspan="1">LMS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MET/50</td><td align="center" rowspan="1" colspan="1">f/f</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">Right upper arm</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Left buttock</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Scalp</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td align="left" rowspan="1" colspan="1">MET/47</td><td align="center" rowspan="1" colspan="1">p/f/p</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">Right thigh</td><td align="center" rowspan="1" colspan="1">LS</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Left shoulder</td><td align="center" rowspan="1" colspan="1">LS</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Right lower leg<sup>&#x02020;</sup></td><td align="center" rowspan="1" colspan="1">LS</td><td align="left" rowspan="1" colspan="1">TD/22</td><td align="center" rowspan="1" colspan="1">f/p/p</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">79</td><td align="center" rowspan="1" colspan="1">Lower leg</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Right thigh</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NED/36</td><td align="center" rowspan="1" colspan="1">p/f</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">76</td><td align="center" rowspan="1" colspan="1">Right lower leg</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Right thigh*</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TD/164</td><td align="center" rowspan="1" colspan="1">p/f</td></tr><tr><td align="center" colspan="13" rowspan="1"><hr/></td></tr><tr><td align="center" colspan="13" rowspan="1"><italic>Different genomic profiles suggestive of second primary tumors</italic></td></tr><tr><td align="center" colspan="13" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">77</td><td align="center" rowspan="1" colspan="1">Right shoulder</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Left thigh</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">Right lower arm</td><td align="center" rowspan="1" colspan="1">LMS</td><td align="left" rowspan="1" colspan="1">NED/163</td><td align="center" rowspan="1" colspan="1">f/f</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">Left lower arm</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Right lower leg</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NED/54</td><td align="center" rowspan="1" colspan="1">f/p</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">Right lower arm</td><td align="center" rowspan="1" colspan="1">MPNST</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Right thigh</td><td align="center" rowspan="1" colspan="1">LMS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NED/56</td><td align="center" rowspan="1" colspan="1">f/p</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">Left thigh (laterally)</td><td align="center" rowspan="1" colspan="1">LMS</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Left thigh (medially)</td><td align="center" rowspan="1" colspan="1">LMS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TD/28</td><td align="center" rowspan="1" colspan="1">p/f</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">Left knee</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Left lower leg</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MET/15</td><td align="center" rowspan="1" colspan="1">f/p</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">Right trunk wall</td><td align="center" rowspan="1" colspan="1">MPNST</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Scalp</td><td align="center" rowspan="1" colspan="1">MPNST</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TD/32</td><td align="center" rowspan="1" colspan="1">f/p</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">F</td><td align="center" rowspan="1" colspan="1">77</td><td align="center" rowspan="1" colspan="1">Right thigh</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Back</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MET/51</td><td align="center" rowspan="1" colspan="1">p/f</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">M</td><td align="center" rowspan="1" colspan="1">76</td><td align="center" rowspan="1" colspan="1">Right foot</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Right thigh</td><td align="center" rowspan="1" colspan="1">MFH/UPS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MET/51</td><td align="center" rowspan="1" colspan="1">p/f</td></tr></tbody></table><table-wrap-foot><fn><p>MFH/UPS = malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma, LMS = leiomyosarcoma, LS = liposarcoma, MPNST = malignant peripheral nerve sheath tumor.</p><p>*Located 15 cm from the first tumor.</p><p>						<sup>&#x02020;</sup>The patient developed one additional LS, left thoracic wall.</p><p>MET: metastases, TD: tumor death, NED: no evidence of disease.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Recurrent high-level amplifications and homozygous deletions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1">Chromosome</th><th align="center" rowspan="1" colspan="1">No of tumors</th><th align="center" rowspan="1" colspan="1">Cytoband</th><th align="center" rowspan="1" colspan="1">Start position</th><th align="center" rowspan="1" colspan="1">Size (Mbp)</th><th align="center" rowspan="1" colspan="1">HLA/Hz del*</th><th align="left" rowspan="1" colspan="1">Cancer related genes</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1p32.1</td><td align="center" rowspan="1" colspan="1">58571482</td><td align="center" rowspan="1" colspan="1">1.2</td><td align="center" rowspan="1" colspan="1">HLA</td><td align="left" rowspan="1" colspan="1"><italic>JUN</italic></td></tr><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1q44</td><td align="center" rowspan="1" colspan="1">241558190</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">Hz del</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3q23</td><td align="center" rowspan="1" colspan="1">141082484</td><td align="center" rowspan="1" colspan="1">0.51</td><td align="center" rowspan="1" colspan="1">Hz del</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3p12.1&#x02013;3</td><td align="center" rowspan="1" colspan="1">78780218</td><td align="center" rowspan="1" colspan="1">7.0</td><td align="center" rowspan="1" colspan="1">HLA</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4q12</td><td align="center" rowspan="1" colspan="1">54016334</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">HLA</td><td align="left" rowspan="1" colspan="1"><italic>PDGFRA, KIT, CHIC2</italic></td></tr><tr><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">6p 12.3&#x02013;21.2</td><td align="center" rowspan="1" colspan="1">37360640</td><td align="center" rowspan="1" colspan="1">11.4</td><td align="center" rowspan="1" colspan="1">HLA</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">9p21.3</td><td align="center" rowspan="1" colspan="1">21647433</td><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1">Hz del</td><td align="left" rowspan="1" colspan="1"><italic>CDKN2A, CDKN2B, MTAP</italic></td></tr><tr><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">10q23.31</td><td align="center" rowspan="1" colspan="1">89538420</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">Hz del</td><td align="left" rowspan="1" colspan="1"><italic>PTEN</italic></td></tr><tr><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">11q13.4&#x02013;5</td><td align="center" rowspan="1" colspan="1">71730097</td><td align="center" rowspan="1" colspan="1">5.3</td><td align="center" rowspan="1" colspan="1">HLA</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">13q14.2</td><td align="center" rowspan="1" colspan="1">47901160</td><td align="center" rowspan="1" colspan="1">0.65</td><td align="center" rowspan="1" colspan="1">Hz del</td><td align="left" rowspan="1" colspan="1"><italic>RB1</italic></td></tr></tbody></table><table-wrap-foot><fn><p>*HLA = high level amplification, Hz del = homozygous deletion.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>